LONDON, UK - October 22, 2025 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for Tristel plc (AIM: TSTL) and is pleased to announce the placement of Anna Wasyl as Chief Financial Officer (CFO).
In the third quarter of 2025 Coulter Partners drove global executive search for a wide range of life sciences, health, and technology organizations.
We successfully placed executives for independent and VC & PE-backed firms, alongside large-cap and mid-cap public companies, filling critical roles across diverse disciplines worldwide.
CEO/ C-suite/ Board
BioBeat is joining the One Nucleus hub for life science innovation
Cambridge, UK: 23 October 2025
Creative Biolabs has developed a multi-layered model system and offers the global community preclinical research tools that better mimic human physiological characteristics.
In vivo disease models bridge the gap between the fundamental science and the drug candidate validation. The rodent models have long been used to understand the cancer mechanisms, immune system responses, and drug action pathways, and model relevance is being enhanced by genetic engineering and humanization technologies.
An online interactive advisory panel on strategy & implementation for international life sciences investment & growth
The lucrative Life Sciences ecosystems in Lausanne, Switzerland, given the uncertainties elsewhere, provide a set of great and tangible opportunities for UK med-tech, pharma, biotech, and digital health business, for international growth.
WHY ATTEND?
Join Discovery Park for a sponsored networking evening for start-up founders, investors, and sector stakeholders at Barclays Eagle Labs.
A Discovery Park sponsored networking evening at Barclays Eagle Labs, Shoreditch: for founders of startups and scale-ups, plus investors, and of interest to other specialist stakeholders in life science and tech.
Amsbio has launched over a range of over 30 independently developed and manufactured organoid culture-related cytokines for researchers working with stem cells and induced pluripotent stem cells (iPSCs). This new range of cytokines is tailored for and validated in organoid culture, ensuring high compatibility and making your research more controlled and reproducible.
Full programme OUT NOW for Beacon’s Manchester Rare Disease Showcase!
Over 15 expert speakers working across the rare disease space will take to the stage on 26 November at the Bridgewater Hall in Manchester to discuss groundbreaking progress in academia, industry, healthcare, and patient advocacy across the UK.
Beacon’s programme will feature talks and discussions on topics that matter most to the rare community today, including:
Xampla is seeking its first ever Creative Lead, to spearhead a complete creative evolution and take full ownership of how the company presents itself, and its products, globally. This is about more than design and content: it’s about becoming the custodian of our brand, reshaping identity, and creative storytelling that will establish us as brand leaders. Building on strong foundations and guiding the company into its next chapter of brand growth, this is an opportunity for someone to really shape how the company and its products are viewed by the world.